Selling cell thawing: Medcision launches early adopter scheme to push tech

By Gareth Macdonald contact

- Last updated on GMT


Related tags: Clinical trial, Technology

Medcision has started pushing its cell therapy thawing technology through an early adopter scheme designed to encourage adoption by firms with candidates in trials.

The idea is to make Thawstar – Medcision’s thawing technology that is designed to precisely control the preparation of frozen cell therapies – available to 30 companies and institutions during of early stage clinical trials.

According to Medcision, eliminating variability in thawing times, thereby improving the quality and comparability of clinical data.

Samuel Kent, chief commercial officer, told us "we are putting Thawstar cell thawing system into the hands of companies and investigators looking to de-risk thawing of cell therapies in clinical trials. By making this technology readily available, for free, we are contributing to the advancement of clinical trial successes which can be negatively impacted by variations in sample handling."

Kent added that: "We are confident that once users see first-hand the consistency and reproducible outcomes experienced with Thawstar they will evaluate all their non-standardized processes and will consider using MedCision’s thawing products going forward​." 

Thawing tech market heats up

Thawing is a hot topic for cell therapy developers. Most biopharmaceutical products are sensitive to temperature changes, but personalized cell therapies are particularly susceptible.

As a result cell therapies are usually frozen at the manufacturing facility before being shipped to the clinic for administration back to the patient.

Demand for thawing technologies has increased prompting the emergence of firm’s like Medcision, which was set up by laboratory tools developer Biocision last September.

Rivals like Asymptote​ have also recognized the surge in demand. In November​ the UK-firm launched CellSeal, a cell thawing system developed in collaboration with Cook Regenetec, a bioprocessing services firm spun-out of medical device maker Cook Medical.

Other firms like Sartorius​ are developing technologies to avoid potential problems during freezing and thawing operations.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more